ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 400 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and efficacy of pentoxifylline versus placebo administered as apoptosis inductor during remission induction phase of pediatric patients with acute lymphoblastic leukemia
Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study
Who cites it
400 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Paediatric acute myeloid leukaemia epidemiology, treatment approaches, and outcomes in africa: A review of the literature.BMC cancer · 2025Pooled it
- Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.Applied health economics and health policy · 2024Pooled it
- Pooled it
- Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis.Annals of hematology · 2022Pooled it
- WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study.Blood advances · 2026Trial
- Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.JCO precision oncology · 2024Trial
- Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.Blood advances · 2021Trial
- Trial
- Trial
- Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.British journal of haematology · 2019Trial
- Off-Target MAP2K7 Inhibition Drives the Antileukemic Activity of the PD-1/PD-L1 inhibitor ACS-69 in Pediatric T-ALL.Research square · 2026Article
- Diagnostic and therapeutic challenges of locally advanced colon cancer complicated with acute lymphoblastic leukemia: A case report.Oncology letters · 2026Article
- Patterns of relapse and survival outcomes in pediatric ALL from a single center cohort under the CCCG ALL 2015 protocol.Discover oncology · 2026Article
- Evaluation of the Effects of 50 Hz Magnetic Field Exposure on the Human Hematopoietic System in Humanized Mice.Bioelectromagnetics · 2026Article
- Differential Expression and Target Gene Analysis of PBMC-Derived microRNAs as Prognostic Biomarkers in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2026Article
- Long non-coding RNA PCAT18 defines a leukemia-specific regulatory network in pediatric T-ALL.Scientific reports · 2026Article
- Space-time clustering of childhood high hyperdiploid B-cell precursor acute lymphoblastic leukemia: a nationwide Swedish study.European journal of epidemiology · 2026Article
- Redefining pediatric leukemia care - innovations in risk assessment and targeted treatment: a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Liquid biopsy in pediatric acute lymphoblastic leukemia.Frontiers in oncology · 2026Review
- Assessment of growth and pain trajectories for children and adolescents receiving chemotherapy for acute lymphoblastic leukemia in Northern Thailand using group-based trajectory modeling.Frontiers in pediatrics · 2026Article
340 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
purposeWe review recent advances in the biologic understanding and treatment of childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify therapeutically challenging subgroups, and suggest future directions of research.
methodsA review of English literature on childhood acute leukemias from the past 5 years was performed.
resultsContemporary treatments have resulted in 5-year event-free survival rates of approximately 80% for childhood ALL and almost 60% for pediatric AML. The advent of high-resolution genome-wide analyses has provided new insights into leukemogenesis and identified many novel subtypes of leukemia. Virtually all ALL and the vast majority of AML cases can be classified according to specific genetic abnormalities. Cooperative mutations involved in cell differentiation, cell cycle regulation, tumor suppression, drug responsiveness, and apoptosis have also been identified in many cases. The development of new formulations of existing drugs, molecularly targeted therapy, and immunotherapies promises to further advance the cure rates and improve quality of life of patients.
conclusionThe application of new high-throughput sequencing techniques to define the complete DNA sequence of leukemia and host normal cells and the development of new agents targeted to leukemogenic pathways promise to further improve outcome in the coming decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.